Atreca Inc - Ordinary Shares - Class A
News
Atreca, Inc. (NASDAQ:BCEL) Sees Significant Decline in Short Interest
Ticker Report Atreca, Inc. (NASDAQ:BCEL Get Free Report) was the target of a large drop in short interest during the month of February. As of February 29th, there was short interest totalling 272,700...\n more…
Laurion Capital Management LP Has $37,000 Stock Position in Atreca, Inc. (NASDAQ:BCEL)
Ticker Report Laurion Capital Management LP lowered its position in shares of Atreca, Inc. (NASDAQ:BCEL Free Report) by 66.7% in the third quarter, according to its most recent 13F filing with the...\n more…
Their company died. Their antimalarial drug lives on with hopes of saving millions of lives
Bizjournals.com - Health Care News Atreca's antibody discovery work goes back to 2012, after it spun out of work at a Stanford University lab and the Bill & Melinda Gates Foundation ponied up the first "serious money."\n more…
Sera Prognostics, Atreca spike after Baker Bros investments
Seeking Alpha - Healthcare Sera Prognostics, Atreca spike after Baker Bros investments...\n more…
Why Is Atreca (BCEL) Stock Up 85% Today?
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nAtreca stock is heading higher on Thursday as investors react to news of Baker Bros. Advisors LP increasing its stake in the...\n more…
Atreca (NASDAQ:BCEL) Shares Down 5.4%
Ticker Report Atreca, Inc. (NASDAQ:BCEL Get Free Report)s share price was down 5.4% during mid-day trading on Wednesday . The company traded as low as $0.12 and last traded at $0.12. Approximately...\n more…